Plancorp, LLC Ionis Pharmaceuticals Inc Transaction History

Plancorp, LLC

$2.42 Billion
Q4 2024

A detailed history of Plancorp, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Plancorp, LLC holds 11,128 shares of IONS stock, worth $362,772. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,128

Previous 11,286 1.4%

Holding current value

$362,772

Previous $452,000 13.94%

% of portfolio

0.02%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$33.73 - $40.36 $5,329 - $6,376	-158 Reduced 1.4%	11,128 $389,000
Q2 2024 Aug 09, 2024	BUY	$36.45 - $47.7 $4,774 - $6,248	131 Added 1.17%	11,286 $537,000
Q2 2023 Jul 26, 2023	SELL	$34.73 - $43.33 $69 - $86	-2 Reduced 0.02%	11,155 $457,000
Q1 2023 May 11, 2023	SELL	$33.58 - $41.2 $1,846 - $2,266	-55 Reduced 0.49%	11,157 $398,000
Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $1,596 - $2,000	-43 Reduced 0.38%	11,212 $423,000
Q3 2022 Nov 10, 2022	BUY	$36.54 - $48.66 $730 - $973	20 Added 0.18%	11,255 $498,000
Q2 2022 Aug 04, 2022	BUY	$31.71 - $43.0 $729 - $989	23 Added 0.21%	11,235 $416,000
Q1 2022 May 13, 2022	SELL	$29.88 - $37.04 $1,852 - $2,296	-62 Reduced 0.55%	11,212 $415,000
Q4 2021 Feb 11, 2022	BUY	$25.61 - $35.1 $3,585 - $4,914	140 Added 1.26%	11,274 $343,000
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $469 - $567	14 Added 0.13%	11,134 $373,000
Q2 2021 Aug 13, 2021	BUY	$34.54 - $47.25 $690 - $945	20 Added 0.18%	11,120 $444,000
Q4 2020 Feb 09, 2021	SELL	$45.3 - $60.27 $906 - $1,205	-20 Reduced 0.18%	11,100 $628,000
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $527,644 - $700,004	11,120 New	11,120 $528,000

Others Institutions Holding IONS

# of Institutions

412

Shares Held

140M

Call Options Held

829K

Put Options Held

789K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.63B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Plancorp, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Plancorp, LLC with notifications on news.

Account